EcoDrugPlus

60s Ribosomal Protein L11

Ensembl ID : ENSJJAG00000022270
Gene Symbol: LOC101601831
2 Cross references
169 Possible Orthologues:

60s Ribosomal Protein L15-Like

Ensembl ID : ENSJJAG00000010816
Gene Symbol: LOC101609152
2 Cross references
160 Possible Orthologues:

60s Ribosomal Protein L23-Like

Ensembl ID : ENSJJAG00000007620
Gene Symbol: LOC101610562
2 Cross references
74 Possible Orthologues:

60s Ribosomal Protein L24 Pseudogene

Ensembl ID : ENSJJAG00000009128
Gene Symbol: LOC101609661
1 Cross references
220 Possible Orthologues:

60s Ribosomal Protein L26-Like

Ensembl ID : ENSJJAG00000012376
Gene Symbol: LOC101593657
2 Cross references
150 Possible Orthologues:

60s Ribosomal Protein L32

Ensembl ID : ENSJJAG00000011123
Gene Symbol: LOC101603958
2 Cross references
76 Possible Orthologues:

60s Ribosomal Protein L37 Pseudogene

Ensembl ID : ENSJJAG00000002005
Gene Symbol: LOC101596906
1 Cross references
133 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSJJAG00000003447
Gene Symbol: LOC105944014
2 Cross references
23 Possible Orthologues:

60s Ribosomal Protein L39-Like

Ensembl ID : ENSJJAG00000000071
Gene Symbol: LOC101611641
2 Cross references
186 Possible Orthologues:

60s Ribosomal Protein L6 Pseudogene

Ensembl ID : ENSJJAG00000006614
Gene Symbol: LOC101601918
1 Cross references
399 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSJJAG00000015039
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSJJAG00000020057
Gene Symbol: ADAM17
3 Cross references
282 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).